Alterity Therapeutics (ASX:ATH) Days Payable: 0.00 (As of Dec. 2025)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
34 GF Score
Price A$0.56
View Full Analysis

What is Alterity Therapeutics Days Payable?

Alterity Therapeutics ASX:ATH -1.75% 34 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 34/100. Among 707 Biotechnology companies, Alterity Therapeutics ranks worse than 141442.57% on this metric.

Alterity Therapeutics's average Accounts Payable for the three months ended in Dec. 2025 was A$1.60 Mil. Alterity Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2025 was A$0.00 Mil.

The historical rank and industry rank for Alterity Therapeutics's Days Payable or its related term are showing as below:

ASX:ATH's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Alterity Therapeutics's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00). stayed the same

Alterity Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Days Payable Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:ATH vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Alterity Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Days Payable falls into.


ASX:ATH
34GF Score
Alterity Therapeutics Ltd ASX:ATH
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Alterity Therapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

Days Payable (A: Jun. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jun. 2024 ) + Accounts Payable (A: Jun. 2025 )) / count ) / Cost of Goods Sold (A: Jun. 2025 )*Days in Period
=( (0.581 + 0.538) / 2 ) / 0*365
=0.5595 / 0*365
=N/A

Alterity Therapeutics's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (0 + 1.596) / 1 ) / 0*365 / 4
=1.596 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Alterity Therapeutics (ASX:ATH) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alterity Therapeutics and its competitors. According to the industry distribution chart, Alterity Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry.
Is Alterity Therapeutics' Days Payable too high?
Alterity Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Alterity Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alterity Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #999999 out of 707 companies for Days Payable. This places Alterity Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alterity Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alterity Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Days Payable of 0.00. The current Days Payable is 0.00. Alterity Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for ASX:ATH

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price